219 related articles for article (PubMed ID: 26246476)
21. Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival.
Dadras SS; Paul T; Bertoncini J; Brown LF; Muzikansky A; Jackson DG; Ellwanger U; Garbe C; Mihm MC; Detmar M
Am J Pathol; 2003 Jun; 162(6):1951-60. PubMed ID: 12759251
[TBL] [Abstract][Full Text] [Related]
22. Revisiting determinants of prognosis in cutaneous melanoma.
Weiss SA; Hanniford D; Hernando E; Osman I
Cancer; 2015 Dec; 121(23):4108-23. PubMed ID: 26308244
[TBL] [Abstract][Full Text] [Related]
23. Hypoxia regulation of the cell cycle in malignant melanoma: putative role for the cyclin-dependent kinase inhibitor p27.
Murphy M; Carlson JA; Keough MP; Claffey KP; Signoretti S; Loda M
J Cutan Pathol; 2004 Aug; 31(7):477-82. PubMed ID: 15239677
[TBL] [Abstract][Full Text] [Related]
24. Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome.
Jönsson G; Busch C; Knappskog S; Geisler J; Miletic H; Ringnér M; Lillehaug JR; Borg A; Lønning PE
Clin Cancer Res; 2010 Jul; 16(13):3356-67. PubMed ID: 20460471
[TBL] [Abstract][Full Text] [Related]
25. Protein expression of the cell-cycle inhibitor p27Kip1 in malignant melanoma: inverse correlation with disease-free survival.
Flørenes VA; Maelandsmo GM; Kerbel RS; Slingerland JM; Nesland JM; Holm R
Am J Pathol; 1998 Jul; 153(1):305-12. PubMed ID: 9665492
[TBL] [Abstract][Full Text] [Related]
26. Lower expression of KAI1 as a biomarker of poor survival prognosis of melanoma combined with colorectal cancer metastasis.
Du X; Wang B; Liu L; Li Y; Wang ZX; Zhang GJ; Yang XF
J Int Med Res; 2022 Aug; 50(8):3000605221116758. PubMed ID: 35942551
[TBL] [Abstract][Full Text] [Related]
27. Reduced beta-catenin expression in the cytoplasm of advanced-stage superficial spreading malignant melanoma.
Maelandsmo GM; Holm R; Nesland JM; Fodstad Ø; Flørenes VA
Clin Cancer Res; 2003 Aug; 9(9):3383-8. PubMed ID: 12960126
[TBL] [Abstract][Full Text] [Related]
28. A nine-gene signature predicting clinical outcome in cutaneous melanoma.
Brunner G; Reitz M; Heinecke A; Lippold A; Berking C; Suter L; Atzpodien J
J Cancer Res Clin Oncol; 2013 Feb; 139(2):249-58. PubMed ID: 23052696
[TBL] [Abstract][Full Text] [Related]
29. BRAF-V600 Mutation Heterogeneity in Primary and Metastatic Melanoma: A Study With Pyrosequencing and Immunohistochemistry.
Yaman B; Kandiloğlu G; Akalin T
Am J Dermatopathol; 2016 Feb; 38(2):113-20. PubMed ID: 26630683
[TBL] [Abstract][Full Text] [Related]
30. Prognostic significance of cyclooxygenase 2 and phosphorylated Akt1 overexpression in primary nonmetastatic and metastatic cutaneous melanomas.
Soares CD; Borges CF; Sena-Filho M; Almeida OP; Stelini RF; Cintra ML; Graner E; Zecchin KG; Jorge J
Melanoma Res; 2017 Oct; 27(5):448-456. PubMed ID: 28604419
[TBL] [Abstract][Full Text] [Related]
31. Clinicopathological significance of KAI1 expression and epithelial-mesenchymal transition in non-small cell lung cancer.
Zhou L; Yu L; Wu S; Feng Z; Song W; Gong X
World J Surg Oncol; 2015 Aug; 13():234. PubMed ID: 26231404
[TBL] [Abstract][Full Text] [Related]
32. The role of cyclin D1 and Ki-67 in the development and prognostication of thin melanoma.
Kaufmann C; Kempf W; Mangana J; Cheng P; Emberger M; Lang R; Kaiser AK; Lattmann E; Levesque M; Dummer R; Koelblinger P
Histopathology; 2020 Sep; 77(3):460-470. PubMed ID: 32374893
[TBL] [Abstract][Full Text] [Related]
33. Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma.
Gimotty PA; Van Belle P; Elder DE; Murry T; Montone KT; Xu X; Hotz S; Raines S; Ming ME; Wahl P; Guerry D
J Clin Oncol; 2005 Nov; 23(31):8048-56. PubMed ID: 16258103
[TBL] [Abstract][Full Text] [Related]
34. Primary and Metastatic Cutaneous Melanomas Express ALK Through Alternative Transcriptional Initiation.
Busam KJ; Vilain RE; Lum T; Busam JA; Hollmann TJ; Saw RP; Coit DC; Scolyer RA; Wiesner T
Am J Surg Pathol; 2016 Jun; 40(6):786-95. PubMed ID: 26872010
[TBL] [Abstract][Full Text] [Related]
35. Changes in tumor morphology and cyclin-dependent kinase inhibitor expression in metastatic melanoma treated with selective second-generation BRAF inhibitor.
Curry JL; Falchook GS; Hwu WJ; Torres-Cabala CA; Duvic M; Tetzlaff MT; Prieto VG
Am J Dermatopathol; 2013 Feb; 35(1):125-8. PubMed ID: 22878367
[TBL] [Abstract][Full Text] [Related]
36. [Molecular markers associated to prognosis of melanoma].
Heenen M; Laporte M
Ann Dermatol Venereol; 2003 Nov; 130(11):1025-31. PubMed ID: 14724537
[TBL] [Abstract][Full Text] [Related]
37. The role of BRAF mutations in primary melanoma growth rate and survival.
Mar VJ; Liu W; Devitt B; Wong SQ; Dobrovic A; McArthur GA; Wolfe R; Kelly JW
Br J Dermatol; 2015 Jul; 173(1):76-82. PubMed ID: 25752325
[TBL] [Abstract][Full Text] [Related]
38. High LIFr expression stimulates melanoma cell migration and is associated with unfavorable prognosis in melanoma.
Guo H; Cheng Y; Martinka M; McElwee K
Oncotarget; 2015 Sep; 6(28):25484-98. PubMed ID: 26329521
[TBL] [Abstract][Full Text] [Related]
39. Disease progression and patient survival are significantly influenced by BRAF protein expression in primary melanoma.
Safaee Ardekani G; Jafarnejad SM; Khosravi S; Martinka M; Ho V; Li G
Br J Dermatol; 2013 Aug; 169(2):320-8. PubMed ID: 23550516
[TBL] [Abstract][Full Text] [Related]
40. Expression of CRM1 in human gliomas and its significance in p27 expression and clinical prognosis.
Shen A; Wang Y; Zhao Y; Zou L; Sun L; Cheng C
Neurosurgery; 2009 Jul; 65(1):153-9; discussion 159-60. PubMed ID: 19574837
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
